and approves all study documentation, and oversees the final report preparation and submission process.

4. Accountability

The Formulation Development Supervisor is accountable for ensuring that the study formulations are prepared as per the study design. The Clinical Research Manager is accountable for overseeing the conduct of the bioequivalence study. The QA Manager ensures that all procedures follow regulatory requirements and SOP guidelines.

5. Procedure

5.1 Study Design

Establish the bioequivalence study design based on regulatory requirements and scientific objectives:

1. Study Objective
   1. Define the primary objective of the study: to demonstrate that the test capsule formulation is bioequivalent to the reference formulation in terms of pharmacokinetics, including Cmax (maximum concentration), Tmax (time to maximum concentration), AUC (area under the curve), and T1/2 (half-life).
2. Study Population
   1. Select a suitable number of healthy volunteers or patients (depending on the drug’s therapeutic area) for the study. Ensure that the study population is representative of the intended patient population.
   2. Consider inclusion and exclusion criteria such as age, gender, health status, and prior drug use to ensure that the participants are eligible for the bioequivalence study.
3. Study Design
   1. Design the study as a randomized, two-treatment, two-period, two-sequence, cross-over study with a washout period between doses to minimize carryover effects.
   2. Ensure that the study design follows guidelines from regulatory agencies, such as the FDA or EMA, and is approved by the ethics committee before starting the study.

5.2 Formulation Selection and Preparation

Prepare the reference and test capsule formulations for the study:

1. Reference Formulation
   1. Use the commercially available reference product (innovator product) or the authorized reference product that has been marketed and approved by regulatory agencies.
   2. Ensure that the reference product complies with all necessary quality control and release specifications.
2. Test Formulation
   1. Prepare the test formulation to match the reference formulation in terms of the active pharmaceutical ingredient (API), excipients, and dosage strength.
   2. Ensure that the test formulation meets the required quality standards, including uniformity, dissolution profile, and stability testing, before starting the study.

5.3 Conducting the Bioequivalence Study

Conduct the study by administering the reference and test formulations to the study subjects and collecting the required pharmacokinetic data:

1. Study Administration
   1. Administer a single dose of the reference or test formulation to each subject in each study period, following the randomized treatment allocation (cross-over design).
   2. Ensure that the study subjects fast for the required duration before dosing and adhere to all guidelines for food and drink intake during the study.
2. Sample Collection
   1. Collect blood samples at specified time intervals after dosing to measure plasma concentrations of the API and calculate pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2).
   2. Ensure that blood collection is done at consistent time points for all study participants to ensure accurate data.
3. Monitoring
   1. Monitor the subjects for any adverse events (AEs) during and after the study. Any AEs must be reported and documented according to the study protocol.

5.4 Data Analysis

Analyze the pharmacokinetic data from the bioequivalence study:

1. Bioequivalence Criteria
   1. Compare the pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2) for the reference and test formulations using statistical methods such as analysis of variance (ANOVA).
   2. Ensure that the 90% confidence intervals for Cmax and AUC fall within the acceptable range (usually 80%-125%) to meet the bioequivalence criteria.
2. Statistical Methods
   1. Perform statistical analysis to evaluate the bioequivalence between the two formulations. Use appropriate statistical tests, such as t-tests or ANOVA, depending on the study design and data distribution.

5.5 Reporting the Study Results

Prepare a final report detailing the study results:

1. Data Presentation
   1. Present the results of the pharmacokinetic analysis, including Cmax, Tmax, AUC, and T1/2 for both the reference and test formulations.
   2. Include statistical analysis results, including 90% confidence intervals for Cmax and AUC, to demonstrate bioequivalence.
2. Conclusion
   1. Provide a conclusion based on the results, confirming whether the test formulation meets the bioequivalence criteria and can be considered therapeutically equivalent to the reference formulation.
3. Regulatory Submission
   1. Prepare the study report for submission to regulatory authorities (e.g., FDA, EMA) as part of the application for generic product approval.

5.6 Documentation and Record-Keeping

Ensure that all study-related documents are properly documented and stored for regulatory compliance:

1. Study Documentation
   1. Document the study protocol, study reports, raw data, statistical analysis, and any deviations from the protocol in the study files.
   2. Ensure that all documents are signed off by the relevant personnel (e.g., principal investigator, study coordinator) and stored securely for future reference.

6. Abbreviations

• SOP: Standard Operating Procedure
• API: Active Pharmaceutical Ingredient
• QC: Quality Control
• QA: Quality Assurance
• ANOVA: Analysis of Variance
• Cmax: Maximum Concentration
• Tmax: Time to Maximum Concentration
• AUC: Area Under the Curve

7. Documents

1. Bioequivalence Study Report (Annexure-1)
2. Study Protocol (Annexure-2)
3. Pharmacokinetic Data (Annexure-3)

8. References

• FDA Guidance for Industry: Bioequivalence Studies
• USP <711> – Dissolution Testing
• ICH E6 – Good Clinical Practice

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Bioequivalence Study Report

Date	Study ID	Formulation	Outcome
02/02/2025	BE-001	Test Capsule	Pass Bioequivalence Criteria

Annexure-2: Study Protocol

Protocol No.	Study Design	Subject Enrollment	Sampling Schedule
BE-001	Randomized, Cross-Over	30 Subjects	0, 1, 2, 4, 8 Hours Post-Dose

Annexure-3: Pharmacokinetic Data

Date	Parameter	Test Formulation	Reference Formulation
03/02/2025	Cmax	150 ng/mL	155 ng/mL

Revision History:

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
01/01/2024	1.0	Initial Version	New SOP Creation	QA Head
01/02/2025	2.0	Updated bioequivalence testing procedure	Standardization and clarity	QA Head